In an in vivo study, Pal and colleagues demonstrated that mangiferin suppressed inflammatory lesion in diabetic nephropathy by reducing TNF-α and IL-6 levels along with reduced expression of IKK and subsequent inhibition of NF-κB pathway activation40. Here, IL6 is linked to diabetic kidney disease.